Abstract
Adjuvant treatment options for Stage I seminoma include active surveillance, chemotherapy, and radiotherapy. Active surveillance may not be ideal for the average Indian patient. Of the two accepted adjuvant therapy options, namely single-dose carboplatin chemotherapy and radiotherapy to the retroperitoneal nodes, though it intuitively appears more appealing, a deeper review reveals the potential drawbacks of chemotherapy. This article highlights the misconceptions regarding carboplatin and provides reasons for an argument why radiotherapy is better when a patient with Stage I seminoma chooses to undergo adjuvant treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 1216-1219 |
| Number of pages | 4 |
| Journal | Journal of Cancer Research and Therapeutics |
| Volume | 12 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 01-10-2016 |
All Science Journal Classification (ASJC) codes
- Oncology
- Radiology Nuclear Medicine and imaging
Fingerprint
Dive into the research topics of 'Adjuvant treatment for Stage i seminoma: Why radiotherapy is better than carboplatin'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver